# Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

> **NCT06623409** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 72 (estimated)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** GARDASIL®9 (G9)
- **BIOLOGICAL:** V540B

## Key facts

- **NCT ID:** NCT06623409
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-12
- **Primary completion:** 2026-11-20
- **Final completion:** 2026-11-20
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06623409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06623409, "Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06623409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*